LUND, Sweden, May 13, 2020 /PRNewswire/ -- Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced that the Company's management team will participate in the following upcoming investor conferences:
- UBS Global Healthcare Conference on Monday, May 18, 2020, with a presentation at 11:40 AM EST/ 17:40 CET on the same day
- RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2020
- ABG Life Science Summit on Tuesday, May 26, 2020, with a presentation at 12:30 CET on the same day
- Redeye Orphan Drug Event on Wednesday, May 27, 2020 with presentation 10:10 CET on the same day.
- Citi's European Healthcare Conference Tuesday, June 16, 2020
A link to the presentations and webcasts will be available on the Events & Presentations page of the Company's website at http://www.hansabiopharma.com
Calendar 2020
May 18, 2020
|
UBS Global Healthcare Conference, NYC (virtual)
|
May 19, 2020
|
RBC Global Healthcare Conference, NYC (virtual)
|
May 26, 2020
|
ABG Life Science Summit, Stockholm (virtual)
|
May 27, 2020
|
Redeye Orphan Drug Event, Stockholm (virtual)
|
Jun 16, 2020
|
Citi's European Healthcare Conference, London (virtual)
|
Jun 23, 2020
|
Annual General Meeting
|
Jul 16, 2020
|
Interim Report Jan-Jul 2020
|
Sep 16, 2020
|
Bank of America Merill Lynch Global Healthcare Conf., London
|
Oct 22, 2020
|
Interim Report Jan-Sep 2020
|
Nov 25, 2020
|
Ökonomisk Ugebrev Life Science Conference, Copenhagen
|
For further information, please contact:
Klaus Sindahl
Head of Investor Relations
Hansa Biopharma
Mobile: +46(0)709-298 269
E-mail: klaus.sindahl@hansabiopharma.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-participate-in-five-upcoming-investor-conferences-during-may-and-june,c3109885
The following files are available for download:
View original content:http://www.prnewswire.com/news-releases/hansa-biopharma-to-participate-in-five-upcoming-investor-conferences-during-may-and-june-301058329.html
SOURCE Hansa Biopharma AB